Ayse kevser Demir

Dr. Ayse kevser Demir


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kirik
Ali Kirik
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Nizameddin KocaNizameddin Koca
Nizameddin Koca
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SSsibel demiral sezer
sibel demiral sezer
TDTeoman Doğru
Teoman Doğru
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.

17 July 2020 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
TTTurker Tasliyurt
Turker Tasliyurt
EGErkan Gokce
Erkan Gokce
ŞŞŞafak ŞAHİN
Şafak ŞAHİN
AAAsiye Baris Aslan
Asiye Baris Aslan
ADAyse kevser Demir
Ayse kevser Demir
FKFaruk Kutluturk
Faruk Kutluturk
Introduction: Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome (MetS), insulin resistance (IR) and chronic inflammation. Although familial Mediterranean fever (FMF) patients have no symptoms in the periods between attacks, their subclinical inflammation continues. The aim of the present study was to determine the NAFLD frequency in FMF patients and to evaluate their MetS, IR and lipid profiles. Methods: The study included 54 FMF patients and 54 control subjects. The clinical and demographic characteristics of the subjects were recorded, and the patients’ Pras disease severity score was calculated. IR was determined using the homeostasis model assessment (HOMA) index. MetS was diagnosed using the revised National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP ATP III). Hepatic ultrasonography was used to diagnose NAFLD. Results: NAFLD was observed in 15 FMF patients (27.8%) and 14 controls (25.9%). The difference between the groups was not significant (p=0.828). Similarly, no significant difference was found between the two groups for MetS frequency and HOMA index levels. Fasting plasma glucose was significantly higher in FMF patients, whereas differences between the two groups were not significant for lipid levels and other parameters. When FMF patients with and without NAFLD were compared, no significant difference was found in Pras disease severity score, duration of the disease and daily colchicine dose. Conclusion: The present study showed that NAFLD frequency was not increased in FMF patients, and that patients’ MetS frequency, IR and lipid profiles were not different from control subjects.

18 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ADAyse kevser Demir
Ayse kevser Demir
ŞŞŞafak ŞAHİN
Şafak ŞAHİN
RÇRıza Çıtıl
Rıza Çıtıl
ODOsman Demir
Osman Demir
ZÖZeliha Cansel Özmen
Zeliha Cansel Özmen
Background/Objectives: Insulin resistance (IR) is a key feature of metabolic disorders and a major precursor of type 2 diabetes and cardiovascular disease. The triglyceride–glucose (TyG) index and TyG-based indices—including TyG–body mass index (TyG–BMI), TyG–waist circumference (TyG–WC), and TyG–waist-to-height ratio (TyG–WHtR), have been proposed as simple, cost-effective surrogate markers of IR. However, population-based data from Türkiye are limited. To evaluate the association between TyG-based indices, triglycerides/high-density lipoprotein cholesterol (TG/HDL-C) ratio, and IR defined by Homeostasis Model Assessment–IR (HOMA-IR) in adults from the TEKHAP study—a province-wide, population-based survey in Tokat, Türkiye. Methods: A total of 1854 adults (≥20 years) were included in the analysis. Physiologically implausible HOMA-IR outliers were identified using statistical criteria and excluded. IR was defined as HOMA-IR ≥ 2.46, previously validated in this population. TyG and its derivatives were calculated from fasting triglyceride, glucose, and anthropometric measurements. Group comparisons between IR and non-IR individuals, correlation analyses, receiver operating characteristic (ROC) curves, and multivariate logistic regression models were conducted to evaluate the diagnostic and independent associations of these surrogate markers with IR. Results: IR prevalence was 27.2%. Participants with IR had significantly higher triglycerides, fasting glucose, insulin, C-peptide, BMI, and waist circumference and lower HDL-C levels (all p < 0.001). All TyG-based indices were higher in the IR group and showed weak-to-moderate positive correlations with HOMA-IR. TyG–BMI showed the highest diagnostic accuracy in ROC curve analyses (AUC = 0.765); however, this association could not be interpreted as an independent predictive effect in adjusted models because of collinearity with BMI. In multivariable logistic regression, the TyG index demonstrated the strongest independent association with IR (OR = 4.14; 95% CI: 3.32–5.18; p < 0.001), while TyG–WC and the TG/HDL-C ratio also retained significant independent predictive value. Conclusions: The TyG index showed the strongest independent association with IR, while the TG/HDL-C ratio and TyG–WC also demonstrated significant independent predictive value. TyG-based indices may represent practical, low-cost surrogate markers for early metabolic risk stratification in community settings; however, their role in formal screening strategies requires external validation and calibration in independent populations.

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AAAli AKIN
Ali AKIN
ADAyse kevser Demir
Ayse kevser Demir
ZÖZeliha Cansel Özmen
Zeliha Cansel Özmen
The delayed increase in serum creatinine levels poses challenges in the timely diagnosis of acute kidney injury. This study aimed to investigate the relationship between serum angiotensinogen and urinary angiotensinogen levels and the prognosis of renal function in patients diagnosed with acute kidney injury.

2 January 2026 in Postgraduate Medicine
Verified
Journal Article
Closed access
BTBurcin Atak Tel
Burcin Atak Tel
İBİfakat İrem Biçer
İfakat İrem Biçer
IBIsil Bavunoglu
Isil Bavunoglu
NONur Düzen Oflas
Nur Düzen Oflas
MTMelisa Sahin Tekin
Melisa Sahin Tekin
SKSelma Karaahmetoglu
Selma Karaahmetoglu
Hashimoto's thyroiditis (HT) is a T-cell mediated autoimmune disease characterized by the progressive destruction of thyroid gland. Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score and systemic inflammatory index (SII) are novel markers of inflammation. We aimed to compare HALP score and SII values of patients with HT to those in healthy control subjects in the present study. Patients diagnosed with HT and healthy volunteers (as controls) were included in the study. The SII and HALP score were calculated using the following formulas: SII = (Platelet count×Neutrophil count)/Lymphocyte count. HALP score = (Hemoglobin×Serum Albumin×Lymphocyte count)/Platelet count. SII and HALP score of patients with HT and healthy controls were compared. Median SII of the patients with HT (510 (140-3646)) was significantly higher than that of the control subjects (422 (102-2173)) (p < 0.001). Median HALP score of the HT group (47 (7-149)) was significantly lower than that of the control group (54 (10-160)) (p < 0.001). The sensitivity and specificity of SII (when higher than 452%) in detecting HT were 61% and 62%, respectively (AUC: 0.64, p < 0.001, 95%CI: 0.61-0.67). A HALP score lower than 49.5% threshold had 64% sensitivity and 57% specificity in detecting HT (AUC: 0.61, p < 0.001, 95%CI: 0.57-0.64). In logistic regression analysis (considering age, gender, eGFR, TSH, CRP, ESR, BMI), a unit increase in SII increased the risk of HT by 0.3% (p < 0.001, OR: 1.003, 95%CI: 1.002-1.004). HALP score was also an independent risk factor for HT. A unit increase in HALP score decreased the risk of HT by 2% (p < 0.001, OR: 0.977, 95%CI: 0.968-0.985). We recommend that, due to their inexpensive and easily assessable nature, SII and HALP score could serve as additional diagnostic tools in HT.

16 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DYDemet Yavuz
Demet Yavuz
HÇHavva Yasemin Çinpolat
Havva Yasemin Çinpolat
ADAyse kevser Demir
Ayse kevser Demir
NKNezaket Kadı
Nezaket Kadı
ÖKÖznur Kal
Öznur Kal
NANihal Aydemir
Nihal Aydemir
Objective: This study aimed to investigate urinary tract infections (UTIs) and associated risk factors in patients with type 2 diabetes mellitus and chronic kidney disease (CKD), with or without treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i). Methods: We retrospectively analyzed diabetic CKD patients with available urine culture results. Patients were divided into two groups: those receiving SGLT2i therapy and those not receiving it. The groups were compared retrospectively with respect to the development of urinary tract infection at 12-month follow-up, using clinical and laboratory results. Results: A total of 151 patients with T2DM were included, with a median age of 70 years (range: 61–76), and 84 (56%) were female. Among them, 91 (60%) patients were treated with SGLT2i. BMI, plasma glucose levels, and the urine protein/creatinine ratio were significantly lower in the SGLT2i group (p = 0.002, p = 0.049, and p < 0.001, respectively), while serum urea and creatinine levels were significantly higher (p = 0.048 and p = 0.028, respectively). A total of 59 patients (39.1%) had positive urine cultures, 32 of whom (35.2%) were using SGLT2i. There was no statistically significant difference in UTI incidence between SGLT2i users and non-users (p = 0.298). Among patients with positive cultures, Escherichia coli was the most common pathogen, identified in 52.5% (n = 31) of cases. Patients with positive urine cultures were older (p = 0.005), and 39 (66%) were female (p = 0.038). According to logistic regression analysis, advanced age and female sex were identified as independent risk factors for UTI (p = 0.037; Odds Ratio = 2.172, 95% CI: 1.048–4.502 and p = 0.033; Odds Ratio = 2.169, 95% CI: 1.065–4.415, respectively). Conclusions: In diabetic patients with CKD, the use of SGLT2i reduces proteinuria without increasing the risk of urinary tract infections. Advanced age and female sex are independent risk factors for UTI.